Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Mar 07, 2014, 06:19 ET

NEW YORK, March 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Insmed Incorporated Analyst Notes

On February 19, 2014, Insmed Incorporated (Insmed) provided an interim update from its CLEAR-110 study-- an ongoing life-threatening, open-label extension study of once-daily ARIKACE® to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients. The Company informed that the data showed patients taking ARIKACE actually saw their FEV (Forced Expiratory Volume) levels remain above baseline on average, and also experienced a sustained reduction in density of Pa sputum while on treatment. Commenting on the study results, Will Lewis, President and CEO of Insmed, stated, "With the results achieved in our Phase 3 trial, along with these positive interim data, we continue our preparation for regulatory filings with the European Medicines Agency and Health Canada, which remain on target for mid-year." The full analyst notes on Insmed Incorporated are available to download free of charge at:

http://www.AnalystsReview.com/03062014/INSM/report.pdf

Medtronic, Inc. Analyst Notes

On February 26, 2014, Medtronic, Inc.'s (Medtronic) stock went up by 0.63%, closing at $57.81. After opening at $57.63, the stock oscillated in a range of $57.52-$58.22, with total volume of 4.00 million. For the past three day trading period, Medtronic shares went up by 1.21%, compared to the Dow Jones Industrial Average which gained 0.59% during the same period. The full analyst notes on Medtronic, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/MDT/report.pdf

CR Bard Inc. Analyst Notes

On February 26, 2014, CR Bard Inc.'s (CR Bard) stock went up by 0.76%, ending the day at $143.04. The stock opened at $142.04, and traded in a range of $141.68-$144.06 during the session. Over the past three day trading period, the Company's stock went up by 1.04%, compared to the S&P 500 which advanced 0.49% during the same period. The full analyst notes on CR Bard Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/BCR/report.pdf

Laboratory Corp. of America Holdings Analyst Notes

On February 24, 2014, Laboratory Corp. of America Holdings (LabCorp) announced that an agreement has been entered into with Thermo Fisher Scientific, Inc (Thermo Fisher), under which the Company gets access to latter's Thermo Scientific ImmunoCAP™ allergy testing portfolio of more than 600 allergens and 100 allergen components. Commenting on the agreement, Dr. Mark Brecher, LabCorp's Chief Medical Officer, stated, "LabCorp offers an extensive test menu which supports a diagnosis of allergy and, just as importantly, can assist in ruling out allergies as a source of symptoms and thereby suggest other etiologies. We will continue to offer a comprehensive range of tests for regional allergies, food allergies, oral allergy syndrome, pediatric allergens and workplace allergy exposures, and we will develop customized panels to improve treatment practices and enhance patient outcomes." The full analyst notes on Laboratory Corp. of America Holdings are available to download free of charge at:

http://www.AnalystsReview.com/03062014/LH/report.pdf

Acceleron Pharma, Inc. Analyst Notes

On February 26, 2014, Acceleron Pharma, Inc. (Acceleron) reported its Q4 2013 and full year 2013 financial results. Collaboration revenue of Acceleron went up to $11.5 million in the quarter and to $57.2 million in full year 2013, compared to $4.0 million in Q4 2012 and $15.3 million in full year 2012.

For the quarter, net loss applicable to common shareholders was $18.1 million, or $0.64 per diluted share, compared to net loss applicable to common shareholders of $17.1 million, or $7.10 per diluted share, in Q4 2012. Full year 2013 net loss applicable to common shareholders was $39.0 million, or $4.15 per diluted share, compared to net loss applicable to common shareholders of $59.6 million, or $24.84 per diluted share, in full year 2012. Acceleron stated that Q4 2013 and full year 2013 results were affected by the expenses associated with marking to market outstanding warrants to purchase of common stock. The full analyst notes on Acceleron Pharma, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/XLRN/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

SOURCE Analysts Review